Superb talk by Dr. Sripal Bangalore NYU Langone Health on evolving acute #PE care: including validated #CPES score JACC Journals to better risk stratify “normotensive shock” pts [FLASH⚡️trial]. Note: trop, BNP, RV dysfunction, presence of tachycardia, saddle PE +/- concomitant DVT #PE RT

Happy Heart Month! ♥️🫀♥️
#gored for the women in your life
#gored for raising awareness of the #1 killer of Women 💃🏻
#gored so we bring equity to heart care for everyone
#gorred on February 2, 2024 with me!
nancyatheart

FDA Approves First Transcatheter Tricuspid Valve Replacement Device dlvr.it/T2D9hp

Sarah Snow, MD Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 JAMA Cardiology Pamela S Douglas Duke Clinical Research Institute Women as One Duke Heart Duke Cardiology Fellows Great to see such a gratifying increase in women training in IC. Although we still have work to do, this shows that the efforts we all have been making in this regard are being rewarded. Dr Roxana Mehran Alexandra Lansky Nadia Sutton Allison Dupont, MD SCAI Now

Setting up for #InterventionalCardiology conference to our gen🫀fellows on the mgmt of femoral access complications. From RP hematoma to PSA💉 & 🎈tamponade/covered stents, understanding the mechanism for a fem bleed informs tx approach; safe initial access is key. #MedEd ❤️ #PGY7

Reviewing a cross-EP/Interventional Cardiology case with your former 🫀cofellow & EP colleague Dr. Edward Kogan. Sharing patients is one of the joys of being in a multimodal field like #Cardiology ! #PGY7 #EPeeps #CathLab

NCSI algorithm presented by Allison Dupont, MD as part of #SHOCKWEEK

Babar Basir xavier prida Navin Kapur Dan Burkhoff MD PhD

Intravascular Imaging–Guided Versus Angiography‐Guided Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Randomized Trials. #AHAJournals @jay_sreenivasa @yasserj94 Aaqib Malik MD MPH James Howard Michael Nanna Ziad Ali @NanjingFirst ahajrnls.org/3O72Im8

Deferred PCI Equally Safe When Decision-making’s Based on IVUS vs FFR dlvr.it/Szqn4C

Now available online MyJSCAI - Society for Cardiovascular Angiography & Interventions SCAI Now Think Tank Proceedings on Coronary Microvascular Dysfunction (CMD) bit.ly/3uF2j3r addressing diagnostic, regulatory and reimbursement, and treatment issues and opportunities.

Navjot Kaur Sobti, MD SCAI Now Thanks! And for those who want to learn HCM, EP & structural indications and technique at a live proctoring course please come to Corewell Health Beaumont in April 24! For #epeeps and #IC

Phenomenal SCAI Now talk by Dr. Srihari S. Naidu, MD on the expanding indications, safety & efficacy of Alcohol Septal Ablation in everything from advanced oHCM to refractory #VT & #Afib , as well as #StructuralHeart disease-namely, in the pre/post #TMVR / #TAVR settings. #SCAI #EPeeps #HCM

Excellent @scai talks by Dr. Andrew M. Goldsweig, MD, MS on everything from LAA occlusion devices🫀to early #IC career tips for success. Though #Watchman & amulet equivalent in ~80% of cases, greater LAA depth (>10 mm), lower LAA width (11-31 mm) +/- eccentric LAA ostia may favor #Amulet . #SCAI

Fantastic SCAI Now session on #IABP indications, troubleshooting & weaning - including🫀 “family feud” do’s/don’t’s for IABP removal w/Dr. Anna Bortnick MD, PhD, MSc. If #MCS escalation required for refractory #shock - can use 0.014” platinum plus/mailman wire, 0.018” or 0.025” wire for exchange

Feasibility of coronary access following TAVR. CT predicted coronary access Harold Dauerman Philipp Blanke Mohamed Abdel-Wahab Giuseppe_Tarantini Kendra J. Grubb M.D. @paulmahoneyMD Christine Chung Dr. Gilbert Tang #AHAJournals #cardiotwitter ahajrnls.org/3t2AeTn

Women of the #CathLab 🫀SCAI Now: beyond excited to have met Dr. Anna Bortnick MD, PhD, MSc SCAIWIN after a high-yield session on #IABP myths/mgmt/troubleshooting strategies! Amazing meeting of the minds Tani Kahlon MD, MBA discussing MCS eval in #SCAI Stage C-D #shock pts. #HF #SCAI Fellows #WIC 🫀

Terrific talk by Dr. John Messenger SCAI Now on safety/efficacy of SAPIEN3🫀 mitral ViV in pts at prohibitive surgical risk for redo #MVr . Pre-ViV planning enhanced by CT, assessment of T-ID & neo-LVOT to predict risk of LVOTo; 5-yr data from MITRAL trial has shown 80% survival #SCAI